Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Helen G. Haggerty"'
Autor:
Helen G. Haggerty, Maggie Dempster
Publikováno v:
Translational Medicine ISBN: 9781003124542
Translational Medicine
Translational Medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10ed2d05521654cf6298c3bd974e109c
https://doi.org/10.1201/9781003124542-16
https://doi.org/10.1201/9781003124542-16
Autor:
Michael J. Graziano, Thomas Brodie, Carol Gleason, Muthafar Al-Haddawi, Kimberly Bonnette, Bridget S Lewis, Jean G Sathish, Helen G. Haggerty
Publikováno v:
Toxicological sciences : an official journal of the Society of Toxicology. 183(1)
BMS-986251 is a RORγt inverse agonist that was in development for the treatment of autoimmune diseases. RORγt is a nuclear hormone receptor and transcription factor that is involved in the differentiation and function of TH17 cells. RORγt-deficien
Autor:
Frank J. Simutis, Joshua T. Gamse, Michael J. Graziano, Helen G. Haggerty, Rashade Haynes, Wendy J. Freebern, Mary Pazian, James Crona, Roderick T. Bunch
Publikováno v:
Toxicology and applied pharmacology. 409
The OX40 receptor plays a crucial co-stimulatory role in T effector cell survival, expansion, cytokine production, and cytotoxicity to tumor cells; therefore, OX40 agonists are being evaluated as anti-cancer immunotherapies, especially in combination
Autor:
Helen G. Haggerty, Danuta J. Herzyk, Rafael Ponce, B.D. Preston, Curtis Maier, R.D. Mellon, Frank R. Brennan, Herve Lebrec, Cris Kamperschroer, D. Weinstock
Publikováno v:
Regulatory Toxicology and Pharmacology. 75:72-80
Profound immunosuppression (e.g., AIDS, transplant therapy) is epidemiologically associated with an increased cancer risk, and often with oncogenic viruses. It is currently unclear how broadly this association translates to therapeutics that modulate
Autor:
Hui Wei, Neil Mathias, Jessica C. Graham, Aaron P. Yamniuk, Bonnie Wang, Irvith M. Carvajal, Julien Susan D, Janet Gould, Helen G. Haggerty, Michael J. Graziano, Jedd Hillegass, Alex Kozhich, Todd Davidson
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 100
Protein therapeutics represent a rapidly growing proportion of new medicines being developed by the pharmaceutical industry. As with any new drug, an Occupational Exposure Limit (OEL) should be developed to ensure worker safety. Part of the OEL deter
Autor:
Helen G. Haggerty, Danuta J. Herzyk
Publikováno v:
The AAPS journal. 20(2)
The development of novel therapies that can harnass the immune system to eradicate cancer is an area of intensive research. Several new biopharmaceuticals that target the immune system rather than the tumor itself have recently been approved and fund
Autor:
Helen G. Haggerty, Matthew S. Holdren, R. Daniel Mellon, Rafael Ponce, Herve Lebrec, Shawn Heidel, Thomas Gelzleichter, Marc Pallardy
Publikováno v:
Journal of Immunotoxicology. 11:1-12
Observational and clinical studies have associated increased cancer risks with primary or acquired immunodeficiencies, autoimmunity, and use of immunotherapies to treat chronic inflammation (e.g. autoimmunity) or support organ engraftment. Understand
Autor:
Dolca Thomas, Martin Rowe, Cris Kamperschroer, James L. Weaver, Fred Wang, Helen G. Haggerty, Thomas T. Kawabata
Publikováno v:
Journal of Immunotoxicology. 9:121-127
Epstein-Barr virus (EBV)-associated lymphomas are a known risk for immunosuppressed individuals. Non-clinical methods to determine the potential of new immunomodulatory compounds to produce EBV-associated lymphomas (hazard identification) have not be
Autor:
Anthony M. Fletcher, John C. Kozlosky, Courtni Newsome, Jean G Sathish, Frank J. Simutis, Michael J. Graziano, Annette Capozzi, Daniel Szatkowski, Karen Price, John J. Engelhardt, Lila Ramaiah, Austin Thekkumthala, Helen G. Haggerty, Jennifer Wheeler, James Crona, Bojing Wang, Wendy J. Freebern, Rima Srour, Todd Bunch
Publikováno v:
Molecular Cancer Therapeutics. 17:LB-B33
Ipilimumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), an inhibitory receptor expressed on activated effector T cells and regulatory T cells (Treg), that inhibits the bin